cytoplasmic factor interacting with RNA polymerase I and mediating the dissociation of paused ternary Pol I transcription complexes. 10 Then, its role in the formation and function of caveolae was defined. 6, 11 CAVIN1 can interact with CAV1 and protect it from lysosome-dependent degradation, 6, 12 although the lack of CAV1 caused by CAVIN1 mutations could induce muscular dystrophy and lipodystrophy in humans. 13 A deficiency of Cavin1 in mice causes macrophage number and phenotype changes in the lungs 14 and leads to glucose intolerance and insulin resistance. 15 The overexpression of CAVIN1 induces cellular senescence in human fibroblasts. 16 Additionally, CAVIN1 participates in the regulation of immunity and has been suggested to protect human vascular endothelial cells from CTL-mediated lysis. 17 According to previous studies on its function in tumor biology, CAVIN1 plays diverse roles in different types of cancer. CAVIN1
has been reported to reduce the invasion of prostate cancer and tumorigenesis of colorectal cancer. 7, 18, 19 CAVIN1 expression is downregulated in breast, colorectal, gastric, and non-small-cell lung cancer [19] [20] [21] [22] and acts as a tumor suppressor in Ewing's sarcoma. 23 However, CAVIN1 shows a tumor-promoting role in pancreatic cancer by interacting with CAV1. 24 Furthermore, CAVIN1 is required for cell proliferation and migration in rhabdomyosarcoma. 25 The knockdown of CAVIN1 reduces multidrug resistance in breast cancer cell line MCF-7/ADR cells. 26 In GBM, it has been shown that CAVIN1 mediated chemoresistance in U251 cell lines, and its expression was upregulated in samples from relapsed GBM patients, but the number of patient samples was limited. 27, 28 A recent study identified an eight-gene signature, including CAVIN1 that could predict the outcome of GBM patients. 29 However, the function of CAVIN1 and its value as an individual prognostic marker in GBM need to be further investigated.
Therefore, this study sought to investigate the expression of CAVIN1 and its value as a prognostic marker in glioma with clinical samples and data from the Cancer Genome Atlas (TCGA), Chinese Glioma Genome Atlas (CGGA), Rembrandt, and Gene Expression Omnibus (GEO) data set (GSE16011). We verified that CAVIN1 is an independent risk factor for glioma malignancy and might be a potential therapeutic target in GBM. Functional annotation of CAVIN1 in GBM was carried out by bioinformatics methods and showed that CAVIN1 serves as a regulator of disrupted angiogenesis and immune response in the microenvironment of GBM. Taken together, the results of this study suggest CAVIN1 as a possible biomarker in developing new antiangiogenesis or therapeutic immune strategies in GBM. 
| MATERIAL S AND ME THODS

| Patient samples
| Protein extraction and western blotting
Protein extraction, quantification, and immunoblotting were performed as described previously. 30, 31 Detailed information is provided in the Appendix S1.
| Immunohistochemistry
Immunostaining was carried out as described previously. 32 Detailed information is provided in the Appendix S1. The results were evaluated with the German immunohistochemical score (GIS) as previously reported, 30, 33, 34 which further divided the patients into low (GIS ≤4) and high (GIS>4) CAVIN1 expression groups, unless men- 
| Data set preparation for CAVIN1 expression and survival analysis
TCGA, CGGA, Rembrandt, and GSE16011 data sets were used for the analysis ofCAVIN1 expression. Data from TCGA, Rembrandt, and GSE16011 were obtained from GlioVis (https://gliovis.bioinfo.cnio.
es/). 35 The detailed procedure is provided in the Appendix S1.
| The receiver operator characteristic (ROC) curve and principal components analysis (PCA)
The ROC curve was drawn, and the area under the ROC curve (AUC) of each cutoff was measured in accordance with previous reports. 36, 37 PCA was carried out with R (version 3.4.2) (https:// cran.r-project.org) to obtain the expression patterns of CAVIN1 in low-grade glioma (LGG) and GBM.
| Microenvironment cell populations-counter (MCP-counter)
Two nonimmune stromal cell (endothelial cells and fibroblasts) and 
| Gene ontology (GO) analysis
Patients were stratified into two groups according to the median expression value of CAVIN1 mRNA. The R package limma (https:// www.bioconductor.org) was used to identify differentially expressed genes with | log2-fold change |>1 and adjusted P value <0.05 in four cohorts. Then, the common upregulated and downregulated genes correlated with a high level of CAVIN1 expression were summarized from each data set. GO analysis was performed using DAVID 6.8
(https://david.ncifcrf.gov/tools.jsp). 
| Gene set enrichment analysis (GSEA) and gene set variation analysis (GSVA)
Gene set enrichment analysis (https://www.broadinstitute.org/ gsea/index.jsp) was performed to explore whether the identified F I G U R E 1 CAVIN1 expression is elevated in glioma and clinically correlated with poor prognosis in glioma patients. A, A heat map describes the expression levels of caveolae-associated genes in LGG and GBM according to TCGA RNAseq data. The 12 genes were clustered into three groups (upregulated; downregulated; no significant difference) (LGG, n = 470; GBM, n = 155, t test). B, Western blot analysis of CAVIN1 in the indicated nontumor and glioma samples. GAPDH served as a loading control. CAVIN1 expression was quantified and normalized to GAPDH (right) (nontumor, n = 3; grade II, n = 3; grade III, n = 3; grade IV, n = 3; ****P < 0.0001, ***P < 0.001; one-way ANOVA). C, Representative western blot result of CAVIN1 in the indicated glioma cells and normal human astrocyte (NHA) samples with GAPDH as a loading control. CAVIN1 expression was quantified and normalized to GAPDH (right) (n = 3; ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05; one-way ANOVA). D, Representative immunohistochemical images of CAVIN1 in grade II, grade III, and GBM samples. Scale bar, 100 μm. E, Kaplan-Meier analyses evaluating the correlation between CAVIN1 protein expression and survival of 74 glioma patients (grade II, n = 14; grade III, n = 27; GBM, n = 33; CAVIN1 high vs low, P = 0.035; log-rank test) sets of genes showed significant differences between the two groups stratified as described above. Normalized enrichment score (NES) and false discovery rate (FDR) were used to determine statistically significant differences. 40 GSVA (https://www.bioconductor.
org) was applied to further verify significant differences between these two groups, according to the gene sets of defined signaling pathways. 
.2). A
Kaplan-Meier survival analysis was used to estimate the survival distribution, followed by the log-rank test to evaluate the difference between stratified groups, using the median value as the cutoff.
The relationships between CAVIN1 and human leukocyte antigen in TCGA. 42 Loci with GISTIC values ≥1 or ≤ −1 were defined as an amplification or deletion, respectively.
Additional information regarding the materials and methods are available in the Appendix S1.
| RE SULTS
| The analysis of caveolae-related genes in glioma identifies CAVIN1 as a gene with increased expression in GBM
We summarized a list of 12 caveolae-associated genes according to previous reports. 43, 44 Then, we compared the expression levels of these genes between LGG and GBM in TCGA RNAseq database, which included 470 LGG and 155 GBM samples. There were seven upregulated genes (CAVIN1, CAV1, CAV2, CD36, EHD2, PRKCDBP, and CAV3) and three downregulated genes (SDPR, MURC, and PACSIN2) in GBM ( Figure 1A ). Furthermore, we analyzed the data from CGGA, GSE16011, and Rembrandt. CAVIN1, CAV1, CAV2, EHD2, and PRKCDBP were the five overlapping upregulated genes in GBM in the four databases, and SDPR was the only overlapping downregulated gene in this cohort (data not shown). Additionally, we performed a univariate Cox regression analysis with the survival data from those four data sets. The result indicated that CAVIN1 was the only upregulated gene that was correlated with the unfavorable survival of GBM patients in all four of these data sets (Table S1 ).
| CAVIN1 is associated with unfavorable prognosis in glioma patients
We next focused on CAVIN1 because of its essential function in multidrug resistance in cancer cells and its identity as a potential outcome biomarker and bona fide glioma gene candidate. ( Figure 1D and Figure S1A ). The data from the immunofluorescence staining also confirmed this result ( Figure S1B ). Similar results were obtained in the other four data sets (TCGA, Figure S1C ; CGGA, Figure S1D ; GSE16011, Figure S1E ; Rembrandt, Figure S1F ). Next,
we explored the potential of CAVIN1 as a biomarker for the prediction of glioma patients' survival. Patients with higher expression of CAVIN1 exhibited poorer prognosis than did those with lower expression of CAVIN1 ( Figure 1E , P = 0.0035, and Figure S2A ). To further validate these results, we examined the correlation between CAVIN1 and prognosis in glioma patients by using multiple data sets. According to TCGA data, there was a trend indicating that lower expression of CAVIN1 was correlated with better outcome in grade II glioma, although a significant difference was not achieved ( Figure S2B ). The analysis of TCGA data also revealed that (Table S2) . We complemented this analysis with a com- TCGA 4502A microarray database (GBM amplification 11.30%, deletion 9.59%) ( Figure S4 ). The data from TCGA RNAseq and 4502A microarray databases showed that there was no mutation of CAVIN1 in glioma. Collectively, these results show that CAVIN1 expression is elevated in malignant glioma and highlight the potential of CAVIN1 as a prognostic marker for glioma.
| CAVIN1 is an independent predictive factor for progressive malignancy in GBM and demonstrates a subtype expression preference
We then characterized the expression preference of CAVIN1 in GBM with four previously defined subtypes of GBM. 46 According to the TCGA RNAseq data set, CAVIN1 expression in the mesenchymal subtype was significantly higher than that in the proneural and neural subtypes ( Figure S5A ). However, there was no significant difference in CAVIN1 expression between the mesenchymal and classical subtypes. Moreover, the mesenchymal subtype exhibited a higher expression level of CAVIN1 than did the other three subtypes in the CGGA RNAseq data set ( Figure S5B ). The results of the ROC curve and AUC measurement confirmed the application of CAVIN1 as a molecule to distinguish between LGG and GBM tumors ( Figure 2G,H) . Similar AUC values were observed in mesenchymal F I G U R E 3 The CAVIN1 expression level enhances the predictive value of IDH1 or EGFR mutation status and MGMT promoter methylation status and confers different responses to radiotherapy. A and B, The comparison of CAVIN1 expression between the groups with wild-type and mutant IDH1 in TCGA (A, IDH1 WT, n = 142; Mut, n = 8) and CGGA (B, IDH1 WT, n = 93; Mut, n = 29) (****, P < 0.0001; t test). C and D, The Kaplan-Meier analyses of patients with wild-type IDH1 survival data from TCGA (C) and CGGA (D) RNAseq databases according to CAVIN1 expression (log-rank test). E and F, The Kaplan-Meier analyses of patients with wild-type EGFR survival data from TCGA 4502A mRNA microarray (E) and CGGA RNAseq databases (F) according to CAVIN1 expression (log-rank test). G and H, The Kaplan-Meier analyses of patients with MGMT methylated promoter survival data from TCGA RNAseq (G) and 4502A mRNA microarray databases (H) according to CAVIN1 expression (log-rank test). I and J, The Kaplan-Meier analyses of survival of glioma patients treated with radiotherapy from TCGA (I) and CGGA (J) according to CAVIN1 expression (log-rank test)
subtypes vs the other three subtypes (Figure 2I,J) . The results of PCA analysis also confirmed the value of CAVIN1 as a marker for recognizing the difference between LGG and GBM ( Figure 2K ,L).
In addition, the data from the Rembrandt, GSE16011, and TCGA 4502A mRNA microarray data sets confirmed the results mentioned above ( Figure S5C-L) . Collectively, these data suggest that CAVIN1 is an independent factor for the prediction of progressive malignancy in GBM.
| Higher CAVIN1 expression with IDH1 and EGFR mutations implied poorer prognosis in GBM patients
IDH1, MGMT, and EGFR are three well-known genes that have important impacts on the survival of GBM patients and their treatment response. [47] [48] [49] [50] Based on these observations, we tested the role of CAVIN1 in the prediction of GBM patient outcome with differential IDH1 and EGFR mutation status and MGMT promoter methylation status. The samples were stratified according to the median value of CAVIN1 mRNA expression combined with IDH1 mutation, MGMT promoter methylation, or EGFR mutation status. First, the analysis revealed a higher expression level of CAVIN1 in GBM patients with wild-type IDH1 than in those with the mutant form ( Figure 3A ,B).
The correlation between CAVIN1 expression and survival of GBM patients with wild-type IDH1 was also analyzed. Although a significant difference was not achieved, the result showed a tendency for lower levels of CAVIN1 expression to be correlated with better patient survival ( Figure 3C , P = 0.0574; D, P = 0.0719). Second, we found that shorter patient survival was accompanied by higher expression of CAVIN1 in patients with wild-type EGFR ( Figure 3E ,F and Figure S6A ,B), which was consistent with the findings of a recent study. 28 Lastly, the analysis combined with MGMT promoter methylation status demonstrated that there was no significant difference in CAVIN1 expression between the groups with methylated and unmethylated promoters ( Figure S6C,D) . In addition, the data from TCGA RNAseq did not confirm the association between CAVIN1 and survival of GBM patients, although there was a significant difference in TCGA 4502A mRNA microarray data set ( Figure 3G ,H and Figure   S6E ,F). Collectively, higher CAVIN1 expression with IDH1 and EGFR mutation implied poorer prognosis in GBM patients.
| CAVIN1 expression suggests different responses to radiotherapy
Radio-and chemotherapy were the two main postsurgical treatments for GBM patients. 4 We conducted survival analyses to ex- 
| Association of CAVIN1 expression with immune and stromal cell populations in the glioma microenvironment
The tumor microenvironment of glioma contains noncancerous cell types including immune and stromal cells, which contribute actively to the regulation of tumor progression and therapeutic response via extensive cross talk with glioma cells in the tumor microenvironment. 51 By using the MCP-counter method 38 with TCGA and CGGA RNAseq data, we evaluated the correlations between CAVIN1 and 
| CAVIN1 is associated with dysregulated angiogenesis and immune response in the tumor microenvironment of GBM
To illustrate the functions and related signaling pathways of CAVIN1, we summarized the overlapping down-and upregulated genes with high CAVIN1 expression from four data sets. There were 41 downregulated and 141 upregulated genes ( Figure S7 and Table S3 ).
Based on these two groups of genes, we performed GO analysis to summarize a list of signaling pathways related to a high level of CAVIN1 expression as shown in Figure 5A ,B. Moreover, GSVA fur- Table S5 ).
In addition, our previous study identified a local immune-related risk signature that consisted of eight genes (FOXO3, IL6, IL10, ZBTB16, CCL18, AIMP1, FCGR2B, and MMP9). 52 We evaluated the correla- 
| D ISCUSS I ON
GBM is characterized by its infiltrative growth pattern and recurrence even after aggressive resection and a combination of chemo-and radiotherapy. Thus, identifying potential prognostic and therapeutic targets for glioma is urgent. To date, increasing evidence shows that caveolae play a crucial role in multiple signaling and cell functions. 53 However, the role of caveolae remains insufficiently characterized in the regulation of cancer-related processes. Here, we employed bioinformatics methods to interpret mRNA expression and survival data of caveolae-related genes from an integrated cohort of four data sets and identified CAVIN1
as the caveolae-related gene with the greatest increase in expression in GBM. We evaluated the expression of the CAVIN1 protein in glioma tissue, and interestingly, CAVIN expression was not only significantly elevated in glioma tissues but also associated with devastating outcomes in glioma patients. This finding indicated the potential of CAVIN1 as a marker for the prediction of patient survival in glioma and was consistent with previous reports, although it was based on a larger sample size. Additionally, we proved that CAVIN1 served as an independent risk factor for progressive malignancy. A higher level of CAVNI1 expression meant reduced survival time in
GBM patients who received radiotherapy. This finding suggested that CAVIN1 might act as a molecule for the response prediction to radiotherapy in GBM, and patients may benefit from therapeutic strategies combining routine radiation and inhibition of CAVIN1.
Moreover, the incorporation of CAVIN1 expression with detection of the MGMT promoter, IDH1 status, or EGFR status could more accurately predict survival in GBM with MGMT promoter methylation, and GBM without IDH1 or EGFR mutation. This result also implied that targeting CAVIN1 may provide novel insight for GBM treatment, although further study is needed to investigate the related mechanisms.
Another important set of findings in this study is that CAVIN1 expression was closely related to stromal and immune cell populations, especially fibroblasts and cytotoxic lymphocytes. The bioinformatics analysis of the upregulated genes related to high CAVIN1 expression revealed a previously undefined association between CAVIN1 and regulation of angiogenesis and local immune response.
Based on these observations, we hypothesized that CAVIN1 may participate in regulating local neovascularization and immune response in the local microenvironment of GBM. Due to its important role in the progression of glioma, CAVIN1 may serve as a novel candidate molecule for developing new antiangiogenic and immunologic strategies against glioma. However, future studies are still needed to deeply clarify the underlying mechanisms of how CAVIN1 regulates the local microenvironment of GBM and maintains therapeutic resistance.
In conclusion, we first profiled the expression pattern and prognostic value of caveolae component proteins in glioma, which identified an elevated expression of CAVIN1 and its potential as a marker to predict patient outcomes in GBM. Second, CAVIN1 not only was preferentially expressed in GBM patients with wild-type IDH1 but also showed a mesenchymal subtype preference. Interestingly, we 
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